This site contains promotional information intended only for healthcare professionals resident in Great Britain
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
The content of this website has been produced in line with the ABRYSVO®▼(Respiratory Syncytial Virus Vaccine [bivalent, recombinant]) Summary of Product Characteristics for Great Britain and is intended for Healthcare Professionals based in Great Britain only. ABRYSVO▼ Prescribing Information for Great Britain click here. ABRYSVO▼ Prescribing Information for Northern Ireland click here.
RSV is a leading cause of lower respiratory tract infection (LRTI)-related hospitalisations in infants in the UK.2
Infants are most vulnerable to RSV hospitalisation in the first 6 months of life.2
In England, it is estimated that, each year, RSV in infants under 6 months leads to:3
64,000 GP appointments
13,000 RSV associated hospitalisations
ABRYSVO is a maternal RSV vaccine that can help protect infants against serious consequences of RSV from birth and through 6 months of life.1
A pregnant woman receives ABRYSVO during 28-36 weeks of gestation.1
The pregnant woman's immune system produces antibodies, which are passed through the placenta to the foetus.4
The infant is born with maternal antibodies helping to protect against RSV infection.4
Understand more about the dosing, administration and storage of ABRYSVO for maternal patients.
Learn more about the safety information of ABRYSVO in pregnant women.
Explore the ABRYSVO resources section for useful videos and materials.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2024 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024